Combination of LINC01212 and BRAF/MEK inhibition as a new therapeutic strategy for melanoma Ghent University
Melanoma is one of the most aggressive and treatment resistant human tumors with mortality rates above 50% for metastatic skin melanoma and up to 80% for metastatic ocular melanoma. The identification of BRAF mutations in skin melanoma has led to the introduction of mutant-specific BRAF inhibitors in the clinic. While mutant BRAF inhibition invokes impressive anti-tumor response initially, unfortunately, all patients rapidly acquire ...